Rein Therapeutics and Qureight broaden life science collaboration
Business Weekly
How is deep learning imaging advancing drug discovery for fibrosis?
Drug Discovery World
The role of NHS Big Data and AI technology in unlocking the future of lung and heart disease treatment
pharmaphorum
Qureight and Remedy Cell to validate RC-0315 in Phase Ib trial for IPF
Clinical Trials Arena
Vicore Pharma to track lung fibrosis trial with Qureight's AI-powered imaging platform
FirstWord PHARMA
Qureight tech deployed in lung fibrosis clinical trial
Health Tech World
Qureight and Avalyn Launch Strategic Partnership in Progressive Pulmonary Fibrosis
Pharma Focus Europe
Qureight and Avalyn launch strategic partnership in pulmonary fibrosis
PharmaTimes Online
Unravelling the most complex disease challenges in history: How AI startups are changing drug discovery
Startups Magazine
Deep Learning–based Segmentation of Computed Tomography Scans Predicts Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis
ATS Journals
8 Questions by Playfair
Medium
Sifted Series A announcement
Sifted
Characterisation of high responders in the AIR C21 Vicore study ERS abstract
ERS Journals
UKTN Pitching to investors
UK Tech News
Automated vascular and fibrotic segmentations associated with IPF mortality ATS abstract
ATS Journals
Cambridge Angels 5 Questions
Imaging adds to mortality prediction in IPF ATS abstract
ATS Journals
AstraZeneca adopts Qureight platform for IPF research
Cambridge Independent